Minerva Neurosciences Files Amended 10-K for Fiscal Year Ended December 31, 2023
Ticker: NERV · Form: 10-K/A · Filed: Feb 26, 2024 · CIK: 1598646
Sentiment: neutral
Topics: 10-K/A, Minerva Neurosciences, NERV, SEC Filing, Fiscal Year 2023
TL;DR
<b>Minerva Neurosciences, Inc. has filed an amended 10-K for the fiscal year ending December 31, 2023, confirming its reporting compliance and stock exchange listing.</b>
AI Summary
Minerva Neurosciences, Inc. (NERV) filed a Amended Annual Report (10-K/A) with the SEC on February 26, 2024. Minerva Neurosciences, Inc. filed an amended 10-K report for the fiscal year ending December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located in Burlington, MA. Common stock of Minerva Neurosciences, Inc. is traded on The Nasdaq Capital Market under the symbol NERV. The filing indicates the company is not a well-known seasoned issuer. Minerva Neurosciences, Inc. has submitted all required reports for the preceding 12 months and the past 90 days.
Why It Matters
For investors and stakeholders tracking Minerva Neurosciences, Inc., this filing contains several important signals. This amended filing provides updated information for the fiscal year 2023, which is crucial for investors to assess the company's current financial and operational status. The confirmation of compliance with SEC filing requirements and the listing on Nasdaq are important indicators of the company's adherence to regulatory standards and market accessibility.
Risk Assessment
Risk Level: low — Minerva Neurosciences, Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, indicating it's an update to previously submitted information rather than a new disclosure of significant events, suggesting a low immediate risk based on this filing alone.
Analyst Insight
Review the specific amendments made in this 10-K/A filing to understand any changes in financial reporting, risk factors, or business operations disclosed by Minerva Neurosciences.
Key Numbers
- 2023-12-31 — Fiscal Year End (Report period)
- 001-36517 — Commission File Number (SEC filing identifier)
- 26-0784194 — I.R.S. Employer Identification No. (Tax identification number)
- NERV — Trading Symbol (Common Stock ticker)
Key Players & Entities
- Minerva Neurosciences, Inc. (company) — Registrant name
- NERV (company) — Trading Symbol
- The Nasdaq Capital Market (company) — Exchange where stock is registered
- Delaware (company) — State of incorporation
- Burlington, MA (company) — Principal executive offices location
- 2023-12-31 (date) — Fiscal year end
- 2024-02-26 (date) — Filing date
FAQ
When did Minerva Neurosciences, Inc. file this 10-K/A?
Minerva Neurosciences, Inc. filed this Amended Annual Report (10-K/A) with the SEC on February 26, 2024.
What is a 10-K/A filing?
A 10-K/A is a amendment to a previously filed annual report, correcting or updating financial statements or disclosures. This particular 10-K/A was filed by Minerva Neurosciences, Inc. (NERV).
Where can I read the original 10-K/A filing from Minerva Neurosciences, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Minerva Neurosciences, Inc..
What are the key takeaways from Minerva Neurosciences, Inc.'s 10-K/A?
Minerva Neurosciences, Inc. filed this 10-K/A on February 26, 2024. Key takeaways: Minerva Neurosciences, Inc. filed an amended 10-K report for the fiscal year ending December 31, 2023.. The company is incorporated in Delaware and its principal executive offices are located in Burlington, MA.. Common stock of Minerva Neurosciences, Inc. is traded on The Nasdaq Capital Market under the symbol NERV..
Is Minerva Neurosciences, Inc. a risky investment based on this filing?
Based on this 10-K/A, Minerva Neurosciences, Inc. presents a relatively low-risk profile. The filing is an amendment to a 10-K, indicating it's an update to previously submitted information rather than a new disclosure of significant events, suggesting a low immediate risk based on this filing alone.
What should investors do after reading Minerva Neurosciences, Inc.'s 10-K/A?
Review the specific amendments made in this 10-K/A filing to understand any changes in financial reporting, risk factors, or business operations disclosed by Minerva Neurosciences. The overall sentiment from this filing is neutral.
How does Minerva Neurosciences, Inc. compare to its industry peers?
Minerva Neurosciences, Inc. operates in the pharmaceutical preparations industry, focusing on neuroscience-related treatments.
Are there regulatory concerns for Minerva Neurosciences, Inc.?
The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including the filing of annual reports (10-K) and amendments.
Industry Context
Minerva Neurosciences, Inc. operates in the pharmaceutical preparations industry, focusing on neuroscience-related treatments.
Regulatory Implications
The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including the filing of annual reports (10-K) and amendments.
What Investors Should Do
- Analyze the specific changes and additions in the amended 10-K filing.
- Verify the company's compliance status with SEC regulations.
- Monitor future filings for updates on the company's drug development and financial performance.
Key Dates
- 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
- 2024-02-26: Filing Date — Date the amended 10-K was filed with the SEC.
Year-Over-Year Comparison
This is an amended 10-K filing, indicating updates to the original report filed for the fiscal year ended December 31, 2023.
Filing Stats: 1,178 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2024-02-23 17:32:06
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share NERV The Nasdaq
- $9.14 — when the last reported sales price was $9.14 per share. The number of shares of Reg
Filing Documents
- d798749d10ka.htm (10-K/A) — 38KB
- d798749dex231.htm (EX-23.1) — 2KB
- d798749dex311.htm (EX-31.1) — 3KB
- d798749dex312.htm (EX-31.2) — 3KB
- 0001193125-24-044724.txt ( ) — 249KB
- nerv-20231231.xsd (EX-101.SCH) — 5KB
- nerv-20231231_cal.xml (EX-101.CAL) — 1KB
- nerv-20231231_def.xml (EX-101.DEF) — 3KB
- nerv-20231231_lab.xml (EX-101.LAB) — 23KB
- nerv-20231231_pre.xml (EX-101.PRE) — 18KB
- d798749d10ka_htm.xml (XML) — 8KB
SIGNATURES
SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MINERVA NEUROSCIENCES, INC. By: /s/ Remy Luthringer, Ph.D. Remy Luthringer, Ph.D. Executive Chairman and Chief Executive Officer (Principal Executive Officer) Date: February 23, 2024